

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-03-04 to 2026-04-03 (30 days)

Generated: 2026-04-03 09:11:45

Executive Summary


Sentiment analysis for Illumina (ILMN) from 2026-03-04 to 2026-04-03. Analyzed 171 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	58	33.9%
Negative	51	29.8%
Neutral	62	36.3%
Total	171	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
Evolution of a truncated nucleocapsid protein enha...	news	2026-04-01	0.869
EBV infection outcomes determined by monocyte and ...	news	2026-03-20	0.840
Microbial growth rates captured using Raman-SIP re...	news	2026-03-18	0.812
I'm a wellness writer — 40 of my favorite products...	news	2026-03-25	0.805
Artificial Intelligence in Oncology: Assessment of...	news	2026-03-30	0.799

Top Negative Events

Title	Source	Date	Score
Publisher Correction: Integrated Liquid Biopsy and...	pubmed	2026 Apr 1	-0.872
Biobanking of gynecologic cancer biospecimens: Dev...	news	2026-03-31	-0.869
New phs004508.v1.p1 Dendritic Cell Redundancy ...	news	2026-03-27	-0.869
Assessment of references for the quantitative anal...	news	2026-03-23	-0.869
Integrating baseline ctDNA-derived tumor metrics e...	pubmed	2026 Mar 3	-0.796